System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Banshi Saboo is an expert in Endocrinology at Diabetes Care & Hormone Clinic (India). As of October 2026, ScienceLeadR ranks Banshi Saboo in the top 1% of experts worldwide for Diabetes Mellitus and Glucose Metabolism Disorders. Banshi Saboo has authored 363 publications, the most recent in 2026, and is an investigator in 8 clinical trials, 1 of them ongoing. SLR score: 1,007 (community average: 125). How the SLR is computed.

LeadR Profile

Banshi Saboo Diabetes Care & Hormone Clinic India
1 007 ScienceLeadR Reputation 1007

Unlock

Register Login
Network Map

Endocrinology

Subspecialties: Cardiology - Public Health - Gastroenterology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2012 - 2026
Source: PubMed

Diabetes Care & Hormone Clinic

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 363

Citations

Citations: 20 990 1st author: 39 Last author: 52 Unique author: 3

Main journals

Diabetes Metab Syndr 37
J Assoc Physicians India 30
Indian J Endocrinol Metab 21
J Diabetol 21
Int J Diabetes Dev Ctries 20

Best Journals

N Engl J Med 3
Lancet Diabetes Endocrinol 2
Nat Med 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Original rDNA Semaglutide Versus Synthetic Copies: Differences and Clinical Implications.
PMID 42769283 — therapeutics, dna, ribosomal, semaglutide		Cureus20260
Corrigendum to "Nutritional considerations for glucagon-like peptide-based therapies: An Asian Indian consensus recommendation" [Obesity Pillars 19 (2026) 100296].
PMID 42694998 — obesity, glucagon, therapeutics, glucagon-like peptides		Obes Pillars20260
Clinical outcomes of a digitally delivered structured lifestyle program in type 2 diabetes: a randomized controlled trial from India.
PMID 42682442 — diabetes mellitus, life style, glycemic control, diabetes mellitus, type 2, digital health		Front Endocrinol (Lausanne)20260
Smoking cessation and harm reduction in type 2 diabetes: development of practical recommendations from the DiaSmokeFree Working Group.
PMID 42645731 — diabetes mellitus, internal medicine, multiple chronic conditions, smoking cessation, smoking, diabetes mellitus, type 2, harm reduction		Intern Emerg Med20260
Psychological burden in Indian adults with type 2 diabetes: prevalence, overlap and predictors of diabetes distress, depression and anxiety - a cross-sectional study.
PMID 42644044 — diabetes mellitus, depression, patient health questionnaire, cross-sectional studies, prevalence, history, mental health, diabetes mellitus, type 2		BMJ Public Health20260

Clinical Studies 8

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

N/A 4
Phase 3 4

By status:

Completed 5
Active not recruiting 1
Recruiting 1
Terminated 1

By type:

Interventional 6
Observational 2

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 0
multicentric5to9 0
multicentricup10 5

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes in India
NCT05502562 — diabetes mellitus, physicians, research, therapeutics, diabetes mellitus, type 2, semaglutide		N/AActive not recruiting2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS